following a full submission:
rivaroxaban (Xarelto) is accepted for restricted use within NHSScotland.
Indication under review: Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with:
- coronary artery disease, or
- symptomatic peripheral artery disease
at high risk of ischaemic events.
SMC restriction: use in patients with stable coronary artery disease that does not require dual antiplatelet therapy.
Addition of rivaroxaban to low-dose aspirin (acetylsalicylic acid) reduced the incidence of a composite outcome that included stroke, cardiovascular death and myocardial infarction, mainly due to reductions in stroke and cardiovascular death. It also increased the incidence of major bleeding.
- Medicine name:
- rivaroxaban (Xarelto)
- SMC ID:
- Co-administered with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events
- Pharmaceutical company
- Bayer Plc
- BNF chapter
- Cardiovascular system
- Submission type
- Full submission
- Date advice published:
- 11 February 2019